At the Myeloma 2015 meeting, Prof Michele Cavo (Bologna University School of Medicine, Bologna, Italy) discusses the heterogeneity and treatment recommendations for high-risk multiple myeloma. Emerging therapeutic strategies in clinical development, including lenalidomide and bortezomib-based treatment regimens, are showing promising activity for this patient group.
Get great new content delivered to your inboxSign up
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest Hemonc news and updates